Left Atrial Appendage Closure for Stroke Prevention in AF The Quest for the Holy Grail∗ by Estes, N.A. Mark
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 6 , N O . 2 4 , 2 0 1 5
ª 2 0 1 5 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 1 0 . 0 1 9EDITORIAL COMMENTLeft Atrial Appendage Closure
for Stroke Prevention in AF
The Quest for the Holy Grail*N.A. Mark Estes III, MDS trokes resulting from embolization of left atrialappendage (LAA) thrombi in patients withatrial ﬁbrillation (AF) account for up to 25% of
the 700,000 cerebrovascular accidents occurring
annually in the United States. LAA, a complex struc-
ture with considerable anatomic variability, has
been appropriately described as the “most lethal
human attachment” (1). Stasis, hypercoagulability,
andendothelial dysfunction (Virchow triad) contribute
to LAA thrombus formation in AF patients. This path-
ophysiological process results in a 5-fold increased
risk for cerebral embolization (2). Stroke is currently
the major cause of disability and the third leading
cause of death in the United States (2). The age-
adjusted prevalence of AF is projected to increase
3-fold by 2050. Accordingly, strokes related to AF
are expected to markedly increase unless effective
prevention strategies are identiﬁed.
Currently, optimal clinical approaches for stroke
prevention in AF patients remain under investigation.
The dominant therapeutic approach is systemic anti-
coagulation (3). Evidence-based medicine from large,
prospective, randomized controlled trials of oral an-
ticoagulants, including warfarin, factor Xa inhibitors,
and direct thrombin inhibitors, support oral anticoag-
ulants as the standard of care to reduce the risk of
stroke (3). However, multiple limitations to anticoag-
ulant therapy with warfarin and the novel oral anti-
coagulants (NOAC) remain (3). Underutilization,
compliance, bleeding, and expense all contribute to a*Editorials published in the Journal of the American College of Cardiology
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Medtronic, Boston Scientiﬁc, and St. Jude Medical.substantial gap between those patients needing and
those receiving anticoagulant therapy. This treatment
gap grows in those most vulnerable to embolic stoke:
the elderly. Many patients with AF who might beneﬁt
from anticoagulation have unfavorable risk proﬁles
with relative or absolute contraindications to anti-
coagulation. Others are unable or unwilling to adhere
to long-term anticoagulation therapy. Thus, there re-
mains a clinical need to develop alternatives to anti-
coagulant therapy to reduce the risk of embolization
from the LAA.
Alternative approaches include LAA excision,
ligation, or closure (1,3,4). These rely on the funda-
mental premise that procedures to exclude the LAA
should prevent strokes while eliminating the disad-
vantages of systemic anticoagulation. Since the
original report of surgical LAA excision over 6 de-
cades ago, a variety of surgical techniques have
evolved. Unfortunately, the evidence supporting
these is severely limited by the absence of appro-
priately controlled prospective randomized trials,
variable surgical techniques, and lack of standard-
ized outcomes measurements (4). Current American
College of Cardiology/American Heart Association
guidelines limit surgical LAA excision to a Class IIb
recommendation (Level of Evidence: C) as an
adjunctive procedure in patients undergoing cardiac
surgery (3).
Recently, meaningful progress has been made in
developing minimally invasive percutaneous trans-
catheter techniques to exclude the LAA and thereby
prevent strokes in AF (5,6). Avoidance of the
morbidity of surgery for LAA excision has driven
development of multiple, less-invasive approaches.
To date, the U.S. Food and Drug Administration has
approved 1, the Watchman device (Boston Scientiﬁc,
Marlborough, Massachusetts), for clinical use (5). This
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2741device has been evaluated in multiple trials compared
with anticoagulant therapy (5,6). After a regulatory
odyssey, Watchman was recently approved for use in
the United States by the Food and Drug Administra-
tion as an alternative to warfarin for stroke preven-
tion (5). The approval speciﬁed indications for use in
patients with nonvalvular AF who are: 1) at increased
risk of stroke and systemic embolism on the basis of
CHADS2 (congestive heart failure history, hyperten-
sion history, age $75 years, diabetes mellitus history,
stroke or transient ischemic attack symptoms previ-
ously) or CHA2DS2-VASc (congestive heart failure,
hypertension, age $75 years, diabetes mellitus, prior
stroke or transient ischemic attack or thromboembo-
lism, vascular disease, age 65 to 75 years, sex cate-
gory) scores; 2) deemed by their physicians to be
suitable for warfarin therapy; and 3) have an appro-
priate rationale to seek a nonpharmacological alter-
native to warfarin, taking into account the safety and
efﬁcacy of the device compared with warfarin (5).
With availability of this device for clinical use,
percutaneous LAA closure now provides a clinically
available alternative to oral anticoagulation or sur-
gery for stroke prevention in selected patients with
AF.
The evidence of clinical effectiveness and safety of
this LAA closure device has been established in a series
of well-performed clinical trials and registries that
were recently analyzed in a patient-level meta-anal-
ysis (6). Although the evidence for approval for clinical
use is robust, multiple issues remain unresolved.
Safety and efﬁcacy alone are insufﬁcient to cause a
paradigm shift toward LAA closure for stroke preven-
tion in AF patients (6,7). In the current health care
environment, economic analyses assessing compara-SEE PAGE 2728tive costs over time are also needed. In this issue of the
Journal, Reddy et al. (7) address this increasingly
important issue with a cost-effectiveness analysis of
warfarin, NOAC, and LAA closure with the Watchman
device in patients with nonvalvular AF. These in-
vestigators conclude that compared with warfarin,
LAA closure is cost-effective at 7 years, whereas NOAC
are cost effective at 16 years. LAA closure becomes the
dominant strategy over NOAC by year 5 and warfarin
by year 10 (7). On the basis of their assumptions and
model, they conclude that the Watchman device is
cost-effective compared with warfarin and offered
better value relative to NOAC (7).
Because cost-effectiveness modeling enables cost,
clinical effectiveness, and patient outcomes to be
taken into account, this novel analysis represents an
important analytic approach for evaluating strokeprevention strategies in AF (7). However, clinicians
should be mindful of the limitations of this cost-
effectiveness model. Out of necessity, the analysis
was performed using indirect comparison methodol-
ogy, with warfarin as the common control. The best
available data from controlled clinical trials support
the notion that the NOAC have a favorable risk/
beneﬁt ratio compared with warfarin. Watchman has
not yet been compared directly to NOAC in prospec-
tive randomized trails. Whether LAA closure provides
a clear beneﬁt when compared with factor Xa in-
hibitors or direct thrombin inhibitors should be
determined by head-to-head comparisons in future
trials.
The clinical inputs for this cost-effectiveness
analysis were on the basis of clinical trial data with
experienced centers implanting LAA closure devices
(7). As acknowledged by the investigators, treatments
in clinical practice rarely achieve the outcomes
observed in clinical trials (7). Clinical trials enroll
selected patients, have lower procedural complica-
tion rates, achieve higher levels of medication
adherence, and monitor patients more intensively.
The high compliance achieved in the Watchman,
NOAC, and warfarin trials have not been and are un-
likely to be achieved in clinical practice. All of the
data used in the analysis had variable time horizons
and were extrapolated to 20 years (7). The conclu-
sions are also highly dependent on assumptions
regarding increases in costs of treatment and moni-
toring over time. It is evident that only prospective
trials of LAA closure devices will give data for an
evidence-based analysis of cost-effectiveness over a
patient’s lifetime.
The approval of Watchman as the initial minimally
invasive percutaneous transcatheter technique to
exclude the LAA as an alternative for stroke preven-
tion in AF brings to the forefront additional issues
beyond safety, efﬁcacy, and cost-effectiveness (6–8).
Among them are selection and training of implanting
centers and mechanisms for rigorous assessment of
outcomes (8). The identiﬁcation of patient cohorts
with the most favorable risk/beneﬁt and cost-
effectiveness analysis, as well as those with the
most unfavorable characteristics, remains an impor-
tant objective of clinical registries (8). Mechanisms
are needed for extension of this technology to the
treatment of other groups of patients not studied in
the randomized and observational clinical studies (8).
As future technologies become available as alterna-
tives to anticoagulation for stroke prevention in AF,
centers with proper resources and training should
oversee deployment into clinical practice. Further-
more, registries to rigorously evaluate short- and
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2742long-term safety, comparative effectiveness, and
cost-effectiveness are needed (8). Despite these
unanswered questions, the evidence from the
Watchman clinical trials and this analysis represent
meaningful progress in the quest for LAA closure as a
clinical strategy for stroke prevention in AF patients.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
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